US20110288107A1 - Topical formulation for a jak inhibitor - Google Patents
Topical formulation for a jak inhibitor Download PDFInfo
- Publication number
- US20110288107A1 US20110288107A1 US13/112,370 US201113112370A US2011288107A1 US 20110288107 A1 US20110288107 A1 US 20110288107A1 US 201113112370 A US201113112370 A US 201113112370A US 2011288107 A1 US2011288107 A1 US 2011288107A1
- Authority
- US
- United States
- Prior art keywords
- formulation
- weight
- component
- pharmaceutical formulation
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SRLPIZNAOXYWLY-QCUBGVIVSA-N *.O=P(=O)OO.[HH].[H][C@@](CC#N)(C1CCCC1)N1C=C(C2=NC=NC3=C2C=CN3)C=N1 Chemical compound *.O=P(=O)OO.[HH].[H][C@@](CC#N)(C1CCCC1)N1C=C(C2=NC=NC3=C2C=CN3)C=N1 SRLPIZNAOXYWLY-QCUBGVIVSA-N 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N *.[H][C@@](CC#N)(C1CCCC1)N1C=C(C2=NC=NC3=C2C=CN3)C=N1 Chemical compound *.[H][C@@](CC#N)(C1CCCC1)N1C=C(C2=NC=NC3=C2C=CN3)C=N1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- QZXPFOACXTYLHE-ZWZQDMJTSA-N N#CC[C@@H](C1CCCC1)N1C=C(C2=C3C=CNC3=NC=N2)C=N1.N#CC[C@H](C1CCCC1)N1C=C(C2=C3C=CNC3=NC=N2)C=N1 Chemical compound N#CC[C@@H](C1CCCC1)N1C=C(C2=C3C=CNC3=NC=N2)C=N1.N#CC[C@H](C1CCCC1)N1C=C(C2=C3C=CNC3=NC=N2)C=N1 QZXPFOACXTYLHE-ZWZQDMJTSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
- Protein kinases regulate diverse biological processes including cell growth, survival, differentiation, organ formation, morphogenesis, neovascularization, tissue repair, and regeneration, among others. Protein kinases also play specialized roles in a host of human diseases including cancer. Cytokines, low-molecular weight polypeptides or glycoproteins, regulate many pathways involved in the host inflammatory response to sepsis. Cytokines influence cell differentiation, proliferation and activation, and can modulate both pro-inflammatory and anti-inflammatory responses to allow the host to react appropriately to pathogens.
- JAKs Janus kinase family
- JAK2 Janus kinase-1
- JAK2 JAK2
- JAK3 also known as Janus kinase, leukocyte
- JAKL protein-tyrosine kinase 2
- TYK2 protein-tyrosine kinase 2
- Cytokine-stimulated immune and inflammatory responses contribute to pathogenesis of diseases: pathologies such as severe combined immunodeficiency (SCID) arise from suppression of the immune system, while a hyperactive or inappropriate immune/inflammatory response contributes to the pathology of autoimmune diseases (e.g., asthma, systemic lupus erythematosus, thyroiditis, myocarditis), and illnesses such as scleroderma and osteoarthritis (Ortmann, R. A., T. Cheng, et al. (2000) Arthritis Res 2(1): 16-32).
- SCID severe combined immunodeficiency
- Jak1 ⁇ / ⁇ mice are runted at birth, fail to nurse, and die perinatally (Rodig, S. J., M. A. Meraz, et al. (1998) Cell 93(3): 373-83). Jak2 ⁇ / ⁇ mouse embryos are anemic and die around day 12.5 postcoitum due to the absence of definitive erythropoiesis.
- the JAK/STAT pathway and in particular all four JAKs, are believed to play a role in the pathogenesis of asthmatic response, chronic obstructive pulmonary disease, bronchitis, and other related inflammatory diseases of the lower respiratory tract.
- Multiple cytokines that signal through JAKs have been linked to inflammatory diseases/conditions of the upper respiratory tract, such as those affecting the nose and sinuses (e.g., rhinitis and sinusitis) whether classically allergic reactions or not.
- the JAK/STAT pathway has also been implicated in inflammatory diseases/conditions of the eye and chronic allergic responses.
- Activation of JAK/STAT in cancers may occur by cytokine stimulation (e.g. IL-6 or GM-CSF) or by a reduction in the endogenous suppressors of JAK signaling such as SOCS (suppressor or cytokine signaling) or PIAS (protein inhibitor of activated STAT) (Boudny, V., and Kovarik, J., Neoplasm. 49:349-355, 2002).
- Activation of STAT signaling, as well as other pathways downstream of JAKs e.g., Akt
- Elevated levels of circulating cytokines that signal through JAK/STAT play a causal role in cachexia and/or chronic fatigue. As such, JAK inhibition may be beneficial to cancer patients for reasons that extend beyond potential anti-tumor activity.
- Inhibition of the JAK kinases is also envisioned to have therapeutic benefits in patients suffering from skin immune disorders such as psoriasis, and skin sensitization.
- skin immune disorders such as psoriasis, and skin sensitization.
- psoriasis vulgaris the most common form of psoriasis, it has been generally accepted that activated T lymphocytes are important for the maintenance of the disease and its associated psoriatic plaques (Gott Kunststoff, A. B., et al, Nat Rev Drug Disc., 4:19-34).
- Psoriatic plaques contain a significant immune infiltrate, including leukocytes and monocytes, as well as multiple epidermal layers with increased keratinocyte proliferation.
- JAK inhibitors Given the usefulness of JAK inhibitors in the treatment of skin disorders, there is a need for improved topical formulations of JAK inhibitors. In particular, there is a need for stable, easily applied formulations for JAK inhibitors with good skin permeation characteristics.
- the formulations of the invention, as well the methods described herein are directed toward this need and other ends.
- a potent JAK1/JAK2 inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, and its pharmaceutically acceptable salts, has previously been described in U.S. Pat. No. 7,598,257, U.S. Patent Publ. No. 2009/0181959, and U.S. Patent Publ. No. 2008/0312259, each of which is incorporated herein by reference in its entirety.
- the present invention describes an oil-in-water formulation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile suitable for topical administration and treatment of skin disorders.
- a pharmaceutical formulation for topical skin application comprising:
- a therapeutically effective amount of a therapeutic agent which is (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
- the present invention also provides a method of treating a skin disorder, comprising applying a pharmaceutical formulation described herein to an area of skin of the patient.
- the present invention also provides a pharmaceutical formulation described herein for use in treatment of a skin disorder in a patient in need thereof.
- the present invention also provides use of a pharmaceutical formulation described herein for the preparation of a medicament for use in treatment of a skin disorder in a patient in need thereof.
- FIG. 1 depicts a flowchart describing the manufacturing process for an oil-in-water formulation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt.
- FIG. 2 depicts the change in lesion score for subjects with chronic plaque psoriasis treated with 0.5%, 1.0%, and 1.5% w/w of an oil-in-water formulation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt (on a free base basis) as compared to treatment with placebo over a 12-week period (the dashed line is baseline).
- FIG. 3 shows photographs of subjects with chronic plaque psoriasis before ( FIG. 3( a )) and after 84 days ( FIG. 3( b )) of treatment with 1.0% w/w of an oil-in-water formulation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt (on a free base basis).
- FIG. 4 shows photographs of subjects with chronic plaque psoriasis before ( FIG. 4( a )) and after 84 days ( FIG. 4( b )) of treatment with 1.0% w/w of an oil-in-water formulation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt (on a free base basis).
- FIG. 5 shows photographs of subjects with chronic plaque psoriasis before ( FIG. 5( a )) and after 84 days ( FIG. 5( b )) of treatment with 1.5% w/w of an oil-in-water formulation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt (on a free base basis).
- FIG. 6 shows photographs of subjects with chronic plaque psoriasis before ( FIG. 6( a )) and after 84 days ( FIG. 6( b )) of treatment with 0.5% w/w of an oil-in-water formulation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt (on a free base basis).
- FIG. 7 shows photographs of subjects with chronic plaque psoriasis before ( FIG. 7( a )) and after 84 days ( FIG. 7( b )) of treatment with 1.0% w/w of an oil-in-water formulation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt (on a free base basis).
- the present invention provides, inter alia, a pharmaceutical formulation for topical skin application, comprising a therapeutically effective amount of
- the pharmaceutical formulation comprises:
- the emulsion comprises water, an oil component, and an emulsifier component.
- the term “emulsifier component” refers, in one aspect, to a substance, or mixtures of substances that maintains an element or particle in suspension within a fluid medium.
- the emulsifier component allows an oil phase to form an emulsion when combined with water.
- the emulsifier component refers to one or more non-ionic surfactants.
- the oil-in-water formulations were found to have better appearance, spreadability and stability as compared with other formulations.
- the formulations have a thick, creamy appearance which allows for good spreadability of the formulation on skin. This good spreadability leads to better skin permeation than comparable anhydrous formulations.
- the oil-in-water formulations showed higher cumulative amounts in studies of transport across human cadaver skin over 24 hours when compared with an anhydrous ointment. While not wishing to be bound by any particular theory, the higher cumulative amounts are believed to be due to better spreadability of the oil-in-water formulation as compared to the anhydrous ointment, resulting in increased surface area for transport.
- a higher viscosity for the oil-in-water formulations also appeared to be preferred with respect to skin permeation as higher viscosity cream formulations had better transport across human cadaver skin as compared with oil-in-water lotions of lower viscosity.
- oil-in-water formulations described herein were found to have good stability over a three-month period when stored at 25° C./60% RH and 40° C./75% RH in aluminum tubes and maintain reasonable viscosity over time.
- water-in-oil formulations displayed syneresis when stored at 40° C. (syneresis means separation of liquid from the emulsion).
- the water-in-oil formulation was also less desirable than the formulations of the invention, because the API dissolved in the base over time, leading to highly variable skin permeation in in vitro studies as well as a lack of an increase in permeability with increasing strength of the formulation.
- formulations described herein are relatively simple to manufacture with a repeatable process of formulation.
- the resultant product is easily packaged.
- the formulations appear to have good stability and relatively consistent permeation profiles.
- the oil component is present in an amount of about 10% to about 40% by weight of the formulation.
- the oil component is present in an amount of about 17% to about 27% by weight of the formulation.
- the oil component is present in an amount of about 20% to about 27% by weight of the formulation.
- the oil component comprises one or more substances independently selected from petrolatums, fatty alcohols, mineral oils, triglycerides, and silicone oils.
- the oil component comprises one or more substances independently selected from white petrolatum, cetyl alcohol, stearyl alcohol, light mineral oil, medium chain triglycerides, and dimethicone.
- the oil component comprises an occlusive agent component.
- the occlusive agent component is present in an amount of about 2% to about 15% by weight of the formulation.
- the occlusive agent component is present in an amount of about 5% to about 10% by weight of the formulation.
- occlusive agent component refers to a hydrophobic agent or mixtures of hydrophobic agents that form an occlusive film on skin that reduces transepidermal water loss (TEWL) by preventing evaporation of water from the stratum corneum.
- TEWL transepidermal water loss
- the occlusive agent component comprises one or more substances selected from fatty acids (e.g., lanolin acid), fatty alcohols (e.g., lanolin alcohol), hydrocarbon oils & waxes (e.g., petrolatum), polyhydric alcohols (e.g., propylene glycol), silicones (e.g., dimethicone), sterols (e.g., cholesterol).
- fatty acids e.g., lanolin acid
- fatty alcohols e.g., lanolin alcohol
- hydrocarbon oils & waxes e.g., petrolatum
- polyhydric alcohols e.g., propylene glycol
- silicones e.g., dimethicone
- sterols e.g., cholesterol
- vegetable or animal fat e.g., cocoa butter
- vegetable wax e.g., Carnauba wax
- wax ester e.g., bees wax
- the occlusive agent component comprises one or more substances selected from lanolin acid fatty alcohols, lanolin alcohol, petrolatum, propylene glycol, dimethicone, cholesterol, cocoa butter, Carnauba wax, and bees wax.
- the occlusive agent component comprises petrolatum.
- the occlusive agent component comprises white petrolatum.
- the oil component comprises a stiffening agent component.
- the stiffening agent component is present in an amount of about 2% to about 8% by weight of the formulation.
- the stiffening agent component is present in an amount of about 3% to about 6% by weight of the formulation.
- the stiffening agent component is present in an amount of about 4% to about 7% by weight of the formulation.
- the term “stiffening agent component” refers to a substance or mixture of substances that increases the viscosity and/or consistency of the formulation or improves the rheology of the formulation.
- the stiffening agent component comprises one or more substances independently selected from fatty alcohols.
- the stiffening agent component comprises one or more substances independently selected from C 12-20 fatty alcohols.
- the stiffening agent component comprises one or more substances independently selected from C 16-18 fatty alcohols.
- the stiffening agent component comprises one or more substances independently selected from cetyl alcohol and stearyl alcohol.
- the oil component comprises an emollient component.
- the emollient component is present in an amount of about 5% to about 15% by weight of the formulation.
- the emollient component is present in an amount of about 7% to about 13% by weight of the formulation.
- the term “emollient component” refers to an agent that softens or soothes the skin or soothes an irritated internal surface.
- the emollient component comprises one or more substances independently selected from mineral oils and triglycerides.
- the emollient component comprises one or more substances independently selected from light mineral oil and medium chain triglycerides.
- the emollient component comprises one or more substances independently selected from light mineral oil, medium chain triglycerides, and dimethicone.
- the water is present in an amount of about 35% to about 65% by weight of the formulation.
- the water is present in an amount of about 40% to about 60% by weight of the formulation.
- the water is present in an amount of about 45% to about 55% by weight of the formulation.
- the emulsifier component is present in an amount of about 1% to about 9% by weight of the formulation.
- the emulsifier component is present in an amount of about 2% to about 6% by weight of the formulation.
- the emulsifier component is present in an amount of about 3% to about 5% by weight of the formulation.
- the emulsifier component is present in an amount of about 4% to about 7% by weight of the formulation.
- the pharmaceutical formulation comprises an emulsifier component and a stiffening agent component, wherein the combined amount of emulsifier component and stiffening agent component is at least about 8% by weight of the formulation.
- the emulsifier component comprises one or more substances independently selected from glyceryl fatty esters and sorbitan fatty esters.
- the emulsifier component comprises one or more substances independently selected from glyceryl stearate, and polysorbate 20.
- the pharmaceutical formulation further comprises a stabilizing agent component.
- the stabilizing agent component is present in an amount of about 0.05% to about 5% by weight of the formulation.
- the stabilizing agent component is present in an amount of about 0.1% to about 2% by weight of the formulation.
- the stabilizing agent component is present in an amount of about 0.3 to about 0.5% by weight of the formulation.
- the term “stabilizing agent component” refers to a substance or mixture of substances that improves the stability of the pharmaceutical formulation and/or the compatibility of the components in the formulation. In some embodiments, the stabilizing agent component prevents agglomeration of the emulsion and stabilizes the droplets in the oil-in-water emulsion.
- the stabilizing agent component comprises one or more substances independently selected from polysaccharides.
- the stabilizing agent component comprises xanthan gum.
- the pharmaceutical formulation further comprises a solvent component.
- the solvent component is present in an amount of about 10% to about 35% by weight of the formulation.
- the solvent component is present in an amount of about 15% to about 30% by weight of the formulation.
- the solvent component is present in an amount of about 20% to about 25% by weight of the formulation.
- solvent component is a liquid substance or mixture of liquid substances capable of dissolving (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile or other substances in the formulation.
- the solvent component is a liquid substance or mixture of liquid substances in which (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, or its pharmaceutically acceptable salt, has reasonable solubility.
- solubilities of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (free base) or its phosphate salt are reported in Table 21.
- a solvent is a substance or mixture thereof, in which (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, or its pharmaceutically acceptable salt (whichever is used), has a solubility of at least about 10 mg/mL or greater, at least about 15 mg/mL or greater, or at least about 20 mg/mL or greater, when measured as described in Example 4.
- the solvent component comprises one or more substances independently selected from alkylene glycols and polyalkylene glycols.
- the solvent component comprises one or more substances independently selected from propylene glycol and polyethylene glycol.
- the therapeutic agent is present in an amount of about 0.5% to about 1.5% by weight of the formulation on a free base basis.
- the therapeutic agent is present in an amount of about 0.5% by weight of the formulation on a free base basis.
- the therapeutic agent is present in an amount of about 1% by weight of the formulation on a free base basis.
- the therapeutic agent is present in an amount of about 1.5% by weight of the formulation on a free base basis.
- the therapeutic agent is (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate.
- the pharmaceutical formulation comprises:
- the pharmaceutical formulation comprises:
- the pharmaceutical formulation comprises:
- the pharmaceutical formulation comprises:
- the pharmaceutical formulation comprises:
- the pharmaceutical formulation comprises:
- the pharmaceutical formulation comprises:
- the pharmaceutical formulation comprises:
- the pharmaceutical formulation comprises:
- the combined amount of the stiffening agent component and the emulsifier component is at least about 8% by weight of the formulation.
- the occlusive agent component comprises a petrolatum
- the stiffening agent component comprises one or more substances independently selected from one or more fatty alcohols
- the emollient component comprises one or more substances independently selected from mineral oils and triglycerides;
- the emulsifier component comprises one or more substances independently selected from glyceryl fatty esters and sorbitan fatty esters;
- the stabilizing agent component comprises one or more substances independently
- the solvent component comprises one or more substances independently selected from alkylene glycols and polyalkylene glycols.
- the occlusive agent component comprises white petrolatum
- the stiffening agent component comprises one or more substances independently selected from cetyl alcohol and stearyl alcohol;
- the emollient component comprises one or more substances independently selected from light mineral oil, medium chain triglycerides, and dimethicone;
- the emulsifier component comprises one or more substances independently selected from glyceryl stearate and polysorbate 20;
- the stabilizing agent component comprises xanthan gum
- the solvent component comprises one or more substances independently selected from propylene glycol and polyethylene glycol.
- the pharmaceutical formulation further comprises an antimicrobial preservative component.
- the antimicrobial preservative component is present in an amount of about 0.05% to about 3% by weight of the formulation.
- the antimicrobial preservative component is present in an amount of about 0.1% to about 1% by weight of the formulation.
- antimicrobial preservative component is a substance or mixtures of substances which inhibits microbial growth in the formulation.
- the antimicrobial preservative component comprises one or more substances independently selected from alkyl parabens and phenoxyethanol.
- the antimicrobial preservative component comprises one or more substances independently selected from methyl paraben, propyl paraben, and phenoxyethanol.
- the pharmaceutical formulation further comprises a chelating agent component.
- chelating agent component refers to a compound or mixtures of compounds that has the ability to bind strongly with metal ions.
- the chelating agent component comprises edetate disodium.
- (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile can be prepared as described in U.S. Pat. No. 7,598,257 and U.S. Patent Publ. No. 2009/0181959, each of which is incorporated herein by reference in its entirety.
- the 1:1 phosphate salt of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile can be prepared as described in U.S. Patent Publ. No. 2008/0312259, which is incorporated herein by reference in its entirety.
- the compounds of the present invention also include pharmaceutically acceptable salts of the compounds disclosed herein.
- pharmaceutically acceptable salt refers to a salt formed by the addition of a pharmaceutically acceptable acid or base to a compound disclosed herein.
- pharmaceutically acceptable refers to a substance that is acceptable for use in pharmaceutical applications from a toxicological perspective and does not adversely interact with the active ingredient.
- Pharmaceutically acceptable salts include, but are not limited to, those derived from organic and inorganic acids such as, but not limited to, acetic, lactic, citric, cinnamic, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, oxalic, propionic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, glycolic, pyruvic, methanesulfonic, ethanesulfonic, toluenesulfonic, salicylic, benzoic, and similarly known acceptable acids.
- organic and inorganic acids such as, but not limited to, acetic, lactic, citric, cinnamic, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, oxalic, propionic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, glycolic, pyruvic, methanes
- % by weight of the formulation on a free base basis of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, or pharmaceutically acceptable salt thereof” means that the % w/w is calculated based on the weight of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile in the total formulation.
- “0.5% w/w on a free base basis” of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate means that for 100 grams of total formulation, there are 0.66 grams of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate in the formulation (which equates to 0.5 grams of the free base, (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile).
- the components are present in exactly the ranges specified (e.g., the term “about” is not present). In some embodiments, “about” means plus or minus 10% of the value.
- each component of the formulation comprises a different substance or mixture of substances.
- component can mean one substance or a mixture of substances.
- fatty acid refers to an aliphatic acid that is saturated or unsaturated. In some embodiments, the fatty acid is in a mixture of different fatty acids. In some embodiments, the fatty acid has between about eight to about thirty carbons on average. In some embodiments, the fatty acid has about 12 to 20, 14-20, or 16-18 carbons on average.
- Suitable fatty acids include, but are not limited to, cetyl acid, stearic acid, lauric acid, myristic acid, erucic acid, palmitic acid, palmitoleic acid, capric acid, caprylic acid, oleic acid, linoleic acid, linolenic acid, hydroxystearic acid, 12-hydroxystearic acid, cetostearic acid, isostearic acid, sesquioleic acid, sesqui-9-octadecanoic acid, sesquiisooctadecanoic acid, behenic acid, isobehenic acid, and arachidonic acid, or mixtures thereof.
- fatty alcohol refers to an aliphatic alcohol that is saturated or unsaturated. In some embodiments, the fatty alcohol is in a mixture of different fatty alcohols. In some embodiments, the fatty alcohol has between about 12 to about 20, about 14 to about 20, or about 16 to about 18 carbons on average. Suitable fatty alcohols include, but are not limited to, stearyl alcohol, lauryl alcohol, palmityl alcohol, cetyl alcohol, capryl alcohol, caprylyl alcohol, oleyl alcohol, linolenyl alcohol, arachidonic alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, chimyl alcohol, and linoleyl alcohol, or mixtures thereof.
- polyalkylene glycol employed alone or in combination with other terms, refers to a polymer containing oxyalkylene monomer units, or copolymer of different oxyalkylene monomer units, wherein the alkylene group has 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
- oxyalkylene employed alone or in combination with other terms, refers to a group of formula —O-alkylene-.
- the polyalkylene glycol is polyethylene glycol.
- sorbitan fatty ester includes products derived from sorbitan or sorbitol and fatty acids and, optionally, poly(ethylene glycol) units, including sorbitan esters and polyethoxylated sorbitan esters.
- the sorbitan fatty ester is a polyethoxylated sorbitan ester.
- sorbitan ester refers to a compound, or mixture of compounds, derived from the esterification of sorbitol and at least one fatty acid.
- Fatty acids useful for deriving the sorbitan esters include, but are not limited to, those described herein.
- Suitable sorbitan esters include, but are not limited to, the SpanTM series (available from Uniqema), which includes Span 20 (sorbitan monolaurate), 40 (sorbitan monopalmitate), 60 (sorbitan monostearate), 65 (sorbitan tristearate), 80 (sorbitan monooleate), and 85 (sorbitan trioleate).
- Other suitable sorbitan esters include those listed in R. C. Rowe and P. J. Shesky, Handbook of pharmaceutical excipients, (2006), 5th ed., which is incorporated herein by reference in its entirety.
- polyethoxylated sorbitan ester refers to a compound, or mixture thereof, derived from the ethoxylation of a sorbitan ester.
- the polyoxethylene portion of the compound can be between the fatty ester and the sorbitan moiety.
- sorbitan ester refers to a compound, or mixture of compounds, derived from the esterification of sorbitol and at least one fatty acid.
- Fatty acids useful for deriving the polyethoyxlated sorbitan esters include, but are not limited to, those described herein.
- the polyoxyethylene portion of the compound or mixture has about 2 to about 200 oxyethylene units.
- the polyoxyethylene portion of the compound or mixture has about 2 to about 100 oxyethylene units. In some embodiments, the polyoxyethylene portion of the compound or mixture has about 4 to about 80 oxyethylene units. In some embodiments, the polyoxyethylene portion of the compound or mixture has about 4 to about 40 oxyethylene units. In some embodiments, the polyoxyethylene portion of the compound or mixture has about 4 to about 20 oxyethylene units.
- Suitable polyethoxylated sorbitan esters include, but are not limited to the TweenTM series (available from Uniqema), which includes Tween 20 (POE(20) sorbitan monolaurate), 21 (POE(4) sorbitan monolaurate), 40 (POE(20) sorbitan monopalmitate), 60 (POE(20) sorbitan monostearate), 60K (POE(20) sorbitan monostearate), 61 (POE(4) sorbitan monostearate), 65 (POE(20) sorbitan tristearate), 80 (POE(20) sorbitan monooleate), 80K (POE(20) sorbitan monooleate), 81 (POE(5) sorbitan monooleate), and 85 (POE(20) sorbitan trioleate).
- TweenTM series available from Uniqema
- Tween 20 POE(20) sorbitan monolaurate
- 21 POE(4)
- POE polyoxyethylene
- the number following the POE abbreviation refers to the number of oxyethylene repeat units in the compound.
- Other suitable polyethoxylated sorbitan esters include the polyoxyethylene sorbitan fatty acid esters listed in R. C. Rowe and P. J. Shesky, Handbook of pharmaceutical excipients, (2006), 5th ed., which is incorporated herein by reference in its entirety.
- the polyethoxylated sorbitan ester is a polysorbate.
- the polyethoxylated sorbitan ester is polysorbate 20.
- the term “glyceryl fatty esters” refers to mono-, di- or triglycerides of fatty acids.
- the glyceryl fatty esters may be optionally substituted with sulfonic acid groups, or pharmaceutically acceptable salts thereof.
- Suitable fatty acids for deriving glycerides of fatty acids include, but are not limited to, those described herein.
- the glyceryl fatty ester is a mono-glyceride of a fatty acid having 12 to 18 carbon atoms.
- the glyceryl fatty ester is glyceryl stearate.
- triglycerides refers to a triglyceride of a fatty acid. In some embodiments, the triglyceride is medium chain triglycerides.
- alkylene glycol refers to a group of formula —O-alkylene-, wherein the alkylene group has 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
- the alkylene glycol is propylene glycol (1,2-propanediol).
- polyethylene glycol refers to a polymer containing ethylene glycol monomer units of formula —O—CH 2 —CH 2 —.
- Suitable polyethylene glycols may have a free hydroxyl group at each end of the polymer molecule, or may have one or more hydroxyl groups etherified with a lower alkyl, e.g., a methyl group.
- derivatives of polyethylene glycols having esterifiable carboxy groups are also suitable.
- Polyethylene glycols useful in the present invention can be polymers of any chain length or molecular weight, and can include branching In some embodiments, the average molecular weight of the polyethylene glycol is from about 200 to about 9000.
- the average molecular weight of the polyethylene glycol is from about 200 to about 5000. In some embodiments, the average molecular weight of the polyethylene glycol is from about 200 to about 900. In some embodiments, the average molecular weight of the polyethylene glycol is about 400.
- Suitable polyethylene glycols include, but are not limited to polyethylene glycol-200, polyethylene glycol-300, polyethylene glycol-400, polyethylene glycol-600, and polyethylene glycol-900. The number following the dash in the name refers to the average molecular weight of the polymer.
- the skin disorder is an autoimmune bullous skin disorder such as pemphigus vulgaris (PV) or bullous pemphigoid (BP).
- the skin disorder is psoriasis (for example, psoriasis vulgaris), atopic dermatitis, skin rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis).
- psoriasis for example, psoriasis vulgaris
- atopic dermatitis for example, skin rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis).
- certain substances including some pharmaceuticals when topically applied can cause skin sensitization.
- co-administration or sequential administration of the topical formulations of the invention together with the agent causing unwanted sensitization can be helpful in treating such unwanted sensitization or dermatitis.
- the present invention further provides a method of treating dermatological side effects of other pharmaceuticals by administration of the compound of the invention.
- numerous pharmaceutical agents result in unwanted allergic reactions which can manifest as acneiform rash or related dermatitis.
- Example pharmaceutical agents that have such undesirable side effects include anti-cancer drugs such as gefitinib, cetuximab, erlotinib, and the like.
- the formulations of the invention can be administered systemically or topically (e.g., localized to the vicinity of the dermatitis) in combination with (e.g., simultaneously or sequentially) the pharmaceutical agent having the undesirable dermatological side effect.
- the formulation of the invention can be administered topically together with one or more other pharmaceuticals, where the other pharmaceuticals when topically applied in the absence of a formulation of the invention cause contact dermatitis, allergic contact sensitization, or similar skin disorder.
- formulation of the invention include topical formulations further comprising an additional pharmaceutical agent which can cause dermatitis, skin disorders, or related side effects.
- the term “individual” or “patient,” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
- the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician.
- the term “treating” or “treatment” refers to one or more of (1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease; (2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology); and (3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
- preventing the disease for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of
- One or more additional pharmaceutical agents such as, for example, chemotherapeutics, anti-inflammatory agents, steroids, immunosuppressants, as well as Bcr-Abl, Flt-3, RAF and FAK kinase inhibitors such as, for example, those described in WO 2006/056399, or other agents can be used in combination with the formulations of the present invention for treatment of JAK-associated diseases, disorders or conditions.
- the one or more additional pharmaceutical agents can be administered to a patient simultaneously or sequentially.
- Example chemotherapeutic include proteosome inhibitors (e.g., bortezomib), thalidomide, revlimid, and DNA-damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.
- proteosome inhibitors e.g., bortezomib
- thalidomide thalidomide
- revlimid thalidomide
- DNA-damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.
- Example steroids include corticosteroids such as dexamethasone or prednisone.
- Example Bcr-Abl inhibitors include the compounds, and pharmaceutically acceptable salts thereof, of the genera and species disclosed in U.S. Pat. No. 5,521,184, WO 04/005281, and U.S. Ser. No. 60/578,491.
- Example suitable Flt-3 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 03/037347, WO 03/099771, and WO 04/046120.
- Example suitable RAF inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 00/09495 and WO 05/028444.
- Example suitable FAK inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 04/080980, WO 04/056786, WO 03/024967, WO 01/064655, WO 00/053595, and WO 01/014402.
- the formulations of the invention can be used in combination with one or more other kinase inhibitors including imatinib, particularly for treating patients resistant to imatinib or other kinase inhibitors.
- a corticosteroid such as dexamethasone is administered to a patient in combination with the compound of the invention where the dexamethasone is administered intermittently as opposed to continuously.
- Another aspect of the present invention relates to formulations comprising a labeled active compound (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quantitating JAK in tissue samples, including human, and for identifying JAK ligands by inhibition binding of a labeled compound. Accordingly, the present invention includes JAK assays that contain such labeled compounds.
- a labeled active compound radio-labeled, fluorescent-labeled, etc.
- the present invention further includes formulations of an isotopically-labeled compound.
- An “isotopically” or “radio-labeled” compound is a compound where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
- Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 18 F, 35 S, 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br, 123 I, 124 I and 131 I.
- the radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro JAK labeling and competition assays, compounds that incorporate 3 H 14 C, 82 Br, 125 I, 131 I, 35 S or will generally be most useful.
- radio-labeled or “labeled compound” is a compound that has incorporated at least one radionuclide.
- the radionuclide is selected from the group consisting of 3 H, 14 C, 125 I, 35 S and 82 Br.
- Kits The present invention also includes pharmaceutical kits useful, for example, in the treatment or prevention of JAK-associated diseases or disorders, such as cancer, which include one or more containers containing a pharmaceutical formulation of the invention.
- kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art.
- Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
- the present invention provides pharmaceutical formulations comprising the components specified in the example formulations (e.g., Example 3), wherein the components are present in about the amounts in Tables 2-5.
- the aqueous layer was back-extracted with three portions of ethyl acetate.
- the combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated.
- the crude product was purified by silica gel chromatography (gradient of ethyl acetate/hexanes) to yield a viscous clear syrup, which was dissolved in ethanol and evaporated several times to remove ethyl acetate, to afford 19.4 g of racemic adduct (93%).
- the enantiomers were separated by preparative-HPLC, (OD-H, 15% ethanol/hexanes) and used separately in the next step to generate their corresponding final product.
- the phosphoric acid salt was shown to be a 1:1 salt by 1 H NMR and crystallinity was confirmed by X-ray powder diffraction (XRPD). Differential scanning calorimetry (DSC) gave a sharp melting peak at about 198.66° C. The product showed little weight loss up to 200° C. by TGA.
- An oil-in-water cream formulation was prepared for (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt (Example 2) at 0.5, 1.0 and 1.5% by weight of the formulation (free base equivalent).
- the compositions for a 15 gram tube are provided in Table 2 below.
- the formulation for three strengths were identical except for adjustments to the purified water quantity based on the amount of active ingredient. All excipients used in the formulation were compendial grade (ie, USP/NF or BP) or are approved for use in topical products.
- FIG. 1 shows a flowchart representation of the process for making the oil-in-water formulation.
- the (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile is referred to as “API” throughout this application.
- a paraben phase was prepared by mixing methyl and propyl parabens with a portion of the propylene glycol (see % in Tables 2-5).
- a xanthan gum phase was prepared by mixing xanthan gum with propylene glycol (see % in Table 2-5).
- An oil phase was then prepared by mixing light mineral oil, glyceryl stearate, polysorbate 20, white petrolatum, cetyl alcohol, stearyl alcohol, dimethicone and medium chain triglycerides. The phase is heated to 70-80° C. to melt and form a uniform mixture.
- the aqueous phase was next prepared by mixing purified water, polyethylene glycol, and disodium EDTA. The phase is heated to 70-80° C.
- step 7 The oil phase from step 3 was then combined under high shear mixing with the mixture from step 6 to form an emulsion.
- Phenoxyethanol was then added to the emulsion from step 7. Mixing was continued, and then the product was cooled under low shear mixing.
- More consistent batches at larger scales could be obtained by adding Example 2 gradually to the aqueous phase and then combining with the other phases.
- more consistent batches could be obtained by slower cooling (e.g., by using room temperature water in the outer jacket of the reactor, rather than lower temperature water.
- the appearance of the cream was visually inspected. Viscosity was measured using a Brookfield viscometer at 25° C. The pH was measured on the final cream formulation. The microbial limit testing is performed as per USP. The fill weight is analyzed as an in-process test during filling of the cream into tubes.
- Results are shown below for a 3.5 kg batches at 0.5%, 1% and 1.5% strength of Example 2 (free base basis (API)) (Table 6).
- the stability data from batches of the cream formulation at 0.5, 1.0 and 1.5% w/w strength stored in 15 gram aluminum tubes is provided in Tables 7-10 and 19-20. Further, stability data from batches of the cream formulation at 0.5, 1.0 and 1.5% w/w strength packaged in amber glass jars (2 oz. with teflon cap) is provided in Tables 13-17, while longer stability data for the 1.0% w/w formulation packaged in 16 oz. amber glass jars is provided in Tables 11-12.
- the preliminary stability data for the drug product did not show any chemical instability after 3 months of storage at 25° C./60% RH and 40° C./75% RH in either packaging configuration. A change in viscosity is seen following 3 months at 40° C./75% RH for formulation stored in amber glass jars. However, physical inspection of the product did not indicate any phase separation.
- Aeruginosa Absent/1 g Absent/1 g NA Absent/1 g MLT ( S. Aureus ) Absent/1 g Absent/1 g NA Absent/1 g MLT (Total Aerobic) ⁇ 10 ⁇ 10 NA ⁇ 10 MLT (Total Yeast ⁇ 10 ⁇ 10 NA ⁇ 10 and Molds)
- Aeruginosa Absent/1 g Absent/1 g NA Absent/1 g MLT ( S. Aureus ) Absent/1 g Absent/1 g NA Absent/1 g MLT (Total Aerobic) ⁇ 10 ⁇ 10 NA ⁇ 10 MLT (Total Yeast and ⁇ 10 ⁇ 10 NA ⁇ 10 Molds)
- the lower viscosity was believed to be due to electrolytic nature of the phosphate salt.
- Viscosities of the formulations and placebo over time are shown in Table 23.
- the 1% dispersed cream (water-in-oil formulation) showed syneresis after two and four weeks of aging at 40° C., while the 1% lotion and 1% solubilized cream formulations (oil-in-water formulations) did not show syneresis.
- the 1% solubilized cream formulation was generally higher in viscosity than the 1% lotion.
- Example 5 The three different topical formulations in Example 5 (Table 20) and the cream formulation in Example 3 (Table 4) were evaluated for transport across human cadaver skin.
- the skin permeation data are summarized in Table 24.
- Significant variability was observed in the transport among the three replicates for each formulation.
- the variability in transport may be due in part to differences in skin samples (donor, region of the body, thickness, etc.).
- the two cream formulations showed higher flux compared to the lotion or ointment.
- the cumulative amount of API transported for the ointment formulation was particularly low in comparison to the other three formulations and this, at least in part, could be due to poor spreadability of the ointment leading to decreased surface area for transport.
- the two cream formulations were selected for further development, one as an oil-in-water (see Example 3 above) and the other as a water-in-oil emulsion base.
- strengths containing 1.0, 1.5, and 2.0% w/w of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate salt were developed for the oil-in water base cream (solubilized cream) and 1.0, 2.0, and 3.0% w/w were developed for the water-in oil base cream (dispersed cream). Procedures for the skin permeation studies are described below.
- the permeability of the API in topical formulations was studied using cadaver human skin samples and Franz diffusion cells. Dermatomed human cadaver skin was obtained from tissue banks while the Franz diffusion cells were custom made. The human cadaver skin samples, sized to fit between the donor and the receiver compartments, were positioned on the Franz diffusion cells. Topical formulations were weighed (20 mg) onto glassine paper, placed formulation side toward the skin and clamped into place. The dosing chamber was covered with parafilm. The reservoir side was filled using saline with 4% albumin. The reservoir was stirred and maintained at 37° C. using a dry block heater (Aungst B. Fatty Acid Skin Penetration Enhancers. Pharm. Res. 1989; 6(3):244-247).
- the permeability of the API in topical formulations was studied using freshly excised mouse skin samples mounted in Franz diffusion cells. Balb/c mice were depilated using a waxing technique four days before the experiment. The morning of the experiment the mice were euthanized and as much of the depilated skin as possible was removed, rinsed and kept moist with 37° C. saline until use. The mouse skin samples, sized to fit between the donor and the receiver compartments, were positioned between the donor and the receiver compartments of the Franz diffusion cells. The opening of the Franz cell was 1 cm 2 . Topical formulations were weighed (20 mg) on to glassine paper, placed formulation side toward the skin and clamped into place. The dosing chamber was covered with parafilm.
- the reservoir side was filled using saline with 4% albumin
- the reservoir was stirred and maintained at 37° C. using a dry block heater (Aungst 1989 (above). At 4 hours, a 1 mL sample was removed and replaced with 1 mL of saline +4% albumin. At 24 hours, the entire reservoir was collected. The tissue was examined visually for any hole or tear. The reservoir side samples were analyzed for concentrations of the API by a LC/MS assay.
- photos were obtained from subjects who signed an informed consent for the photos. Pictures were obtained at baseline (prior to the first application of study treatment) and on day 84 (the last application day for study treatment) (see FIG. 3-7 ). These photos are representative of a subset of the subjects who were treated with the oil-in-water formulations.
- the formulations described herein can also be tested for their efficacies (of inhibiting JAK targets) in the T-cell driven murine delayed hypersensitivity test model.
- the murine skin contact delayed-type hypersensitivity (DTH) response is considered to be a valid model of clinical contact dermatitis, and other T-lymphocyte mediated immune disorders of the skin, such as psoriasis ( Immunol Today. 1998 January; 19(1):37-44).
- Murine DTH shares multiple characteristics with psoriasis, including the immune infiltrate, the accompanying increase in inflammatory cytokines, and keratinocyte hyperproliferation.
- many classes of agents that are efficacious in treating psoriasis in the clinic are also effective inhibitors of the DTH response in mice (Agents Actions. 1993 January; 38(1-2):116-21).
- mice On Day 0 and 1, Balb/c mice are sensitized with a topical application, to their shaved abdomen with the antigen 2,4,dinitro-fluorobenzene (DNFB). On day 5, ears are measured for thickness using an engineer's micrometer. This measurement is recorded and used as a baseline. Both of the animals' ears are then challenged by a topical application of DNFB in a total of 20 ⁇ L (10 ⁇ L on the internal pinna and 10 ⁇ L on the external pinna) at a concentration of 0.2%. Twenty-four to seventy-two hours after the challenge, ears are measured again.
- DNFB 2,4,dinitro-fluorobenzene
- Treatment with the test formulations is given throughout the sensitization and challenge phases (day ⁇ 1 to day 7) or prior to and throughout the challenge phase (usually afternoon of day 4 to day 7). Treatment of the test compounds (in different concentration) is administered topically (topical application of the treatment to the ears). Efficacies of the test formulations are indicated by a reduction in ear swelling comparing to the situation without the treatment. Compounds causing a reduction of 20% or more are considered efficacious. In some experiments, the mice are challenged but not sensitized (negative control).
- the inhibitive effect (inhibiting activation of the JAK-STAT pathways) of the test formulations can be confirmed by immunohistochemical analysis.
- Activation of the JAK-STAT pathway(s) results in the formation and translocation of functional transcription factors.
- the influx of immune cells and the increased proliferation of keratinocytes should also provide unique expression profile changes in the ear that can be investigated and quantified.
- Formalin fixed and paraffin embedded ear sections (harvested after the challenge phase in the DTH model) are subjected to immunohistochemical analysis using an antibody that specifically interacts with phosphorylated STAT3 (clone 58E12, Cell Signaling Technologies).
- test formulations a clinically efficacious treatment for psoriasis
- dexamethasone a clinically efficacious treatment for psoriasis
- Test formulations and the dexamethasone can produce similar transcriptional changes both qualitatively and quantitatively, and both the test formulations and dexamethasone can reduce the number of infiltrating cells.
- Topical administration of the test compounds can produce inhibitive effects, i.e., reduction in the number of infiltrating cells and inhibition of the transcriptional changes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/112,370 US20110288107A1 (en) | 2010-05-21 | 2011-05-20 | Topical formulation for a jak inhibitor |
US14/714,820 US20150250790A1 (en) | 2010-05-21 | 2015-05-18 | Topical formulation for a jak inhibitor |
US16/566,625 US10758543B2 (en) | 2010-05-21 | 2019-09-10 | Topical formulation for a JAK inhibitor |
US16/947,735 US10869870B2 (en) | 2010-05-21 | 2020-08-14 | Topical formulation for a JAK inhibitor |
US16/948,408 US11219624B2 (en) | 2010-05-21 | 2020-09-17 | Topical formulation for a JAK inhibitor |
US17/541,439 US20220211707A1 (en) | 2010-05-21 | 2021-12-03 | Topical formulation for a jak inhibitor |
US17/704,168 US11571425B2 (en) | 2010-05-21 | 2022-03-25 | Topical formulation for a JAK inhibitor |
US17/704,155 US20220370455A1 (en) | 2010-05-21 | 2022-03-25 | Topical formulation for a jak inhibitor |
US17/704,180 US11590136B2 (en) | 2010-05-21 | 2022-03-25 | Topical formulation for a JAK inhibitor |
US18/089,651 US20230277541A1 (en) | 2010-05-21 | 2022-12-28 | Topical formulation for a jak inhibitor |
US18/588,626 US20240245687A1 (en) | 2010-05-21 | 2024-02-27 | Topical formulation for a jak inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34713210P | 2010-05-21 | 2010-05-21 | |
US13/112,370 US20110288107A1 (en) | 2010-05-21 | 2011-05-20 | Topical formulation for a jak inhibitor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/714,820 Continuation US20150250790A1 (en) | 2010-05-21 | 2015-05-18 | Topical formulation for a jak inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110288107A1 true US20110288107A1 (en) | 2011-11-24 |
Family
ID=44201091
Family Applications (11)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/112,370 Abandoned US20110288107A1 (en) | 2010-05-21 | 2011-05-20 | Topical formulation for a jak inhibitor |
US14/714,820 Abandoned US20150250790A1 (en) | 2010-05-21 | 2015-05-18 | Topical formulation for a jak inhibitor |
US16/566,625 Active US10758543B2 (en) | 2010-05-21 | 2019-09-10 | Topical formulation for a JAK inhibitor |
US16/947,735 Active US10869870B2 (en) | 2010-05-21 | 2020-08-14 | Topical formulation for a JAK inhibitor |
US16/948,408 Active US11219624B2 (en) | 2010-05-21 | 2020-09-17 | Topical formulation for a JAK inhibitor |
US17/541,439 Pending US20220211707A1 (en) | 2010-05-21 | 2021-12-03 | Topical formulation for a jak inhibitor |
US17/704,168 Active US11571425B2 (en) | 2010-05-21 | 2022-03-25 | Topical formulation for a JAK inhibitor |
US17/704,155 Abandoned US20220370455A1 (en) | 2010-05-21 | 2022-03-25 | Topical formulation for a jak inhibitor |
US17/704,180 Active US11590136B2 (en) | 2010-05-21 | 2022-03-25 | Topical formulation for a JAK inhibitor |
US18/089,651 Pending US20230277541A1 (en) | 2010-05-21 | 2022-12-28 | Topical formulation for a jak inhibitor |
US18/588,626 Pending US20240245687A1 (en) | 2010-05-21 | 2024-02-27 | Topical formulation for a jak inhibitor |
Family Applications After (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/714,820 Abandoned US20150250790A1 (en) | 2010-05-21 | 2015-05-18 | Topical formulation for a jak inhibitor |
US16/566,625 Active US10758543B2 (en) | 2010-05-21 | 2019-09-10 | Topical formulation for a JAK inhibitor |
US16/947,735 Active US10869870B2 (en) | 2010-05-21 | 2020-08-14 | Topical formulation for a JAK inhibitor |
US16/948,408 Active US11219624B2 (en) | 2010-05-21 | 2020-09-17 | Topical formulation for a JAK inhibitor |
US17/541,439 Pending US20220211707A1 (en) | 2010-05-21 | 2021-12-03 | Topical formulation for a jak inhibitor |
US17/704,168 Active US11571425B2 (en) | 2010-05-21 | 2022-03-25 | Topical formulation for a JAK inhibitor |
US17/704,155 Abandoned US20220370455A1 (en) | 2010-05-21 | 2022-03-25 | Topical formulation for a jak inhibitor |
US17/704,180 Active US11590136B2 (en) | 2010-05-21 | 2022-03-25 | Topical formulation for a JAK inhibitor |
US18/089,651 Pending US20230277541A1 (en) | 2010-05-21 | 2022-12-28 | Topical formulation for a jak inhibitor |
US18/588,626 Pending US20240245687A1 (en) | 2010-05-21 | 2024-02-27 | Topical formulation for a jak inhibitor |
Country Status (35)
Country | Link |
---|---|
US (11) | US20110288107A1 (ja) |
EP (2) | EP3087972A1 (ja) |
JP (7) | JP5849312B2 (ja) |
KR (5) | KR102402137B1 (ja) |
CN (2) | CN105853356B (ja) |
AR (2) | AR084691A1 (ja) |
AU (6) | AU2011255443B2 (ja) |
BR (1) | BR112012029653B1 (ja) |
CA (1) | CA2799928C (ja) |
CL (1) | CL2012003229A1 (ja) |
CO (1) | CO6640250A2 (ja) |
CR (1) | CR20120605A (ja) |
CY (1) | CY1117815T1 (ja) |
DK (1) | DK2574168T3 (ja) |
EA (2) | EA202091303A3 (ja) |
EC (2) | ECSP13012546A (ja) |
ES (1) | ES2581834T3 (ja) |
HK (1) | HK1182313A1 (ja) |
HR (1) | HRP20160841T1 (ja) |
HU (1) | HUE029035T2 (ja) |
IL (1) | IL223084A (ja) |
ME (1) | ME02445B (ja) |
MX (1) | MX338228B (ja) |
MY (2) | MY161078A (ja) |
NZ (1) | NZ603686A (ja) |
PE (1) | PE20130216A1 (ja) |
PL (1) | PL2574168T3 (ja) |
RS (1) | RS54824B1 (ja) |
SG (3) | SG10201910912TA (ja) |
SI (1) | SI2574168T1 (ja) |
SM (1) | SMT201600172B (ja) |
TW (1) | TWI499421B (ja) |
UA (1) | UA111588C2 (ja) |
WO (1) | WO2011146808A2 (ja) |
ZA (1) | ZA202001999B (ja) |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8415362B2 (en) | 2005-12-13 | 2013-04-09 | Incyte Corporation | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US8604043B2 (en) | 2009-05-22 | 2013-12-10 | Incyte Corporation | 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US8722693B2 (en) | 2007-06-13 | 2014-05-13 | Incyte Corporation | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US8765734B2 (en) | 2010-03-10 | 2014-07-01 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US8883806B2 (en) | 2009-01-15 | 2014-11-11 | Incyte Corporation | Processes for preparing JAK inhibitors and related intermediate compounds |
US8933085B2 (en) | 2010-11-19 | 2015-01-13 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US8987443B2 (en) | 2013-03-06 | 2015-03-24 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
US9181271B2 (en) | 2012-11-01 | 2015-11-10 | Incyte Holdings Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
US9359358B2 (en) | 2011-08-18 | 2016-06-07 | Incyte Holdings Corporation | Cyclohexyl azetidine derivatives as JAK inhibitors |
US9382231B2 (en) | 2013-05-17 | 2016-07-05 | Incyte Corporation | Bipyrazole derivatives as JAK inhibitors |
US9487521B2 (en) | 2011-09-07 | 2016-11-08 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US9655854B2 (en) | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US9802957B2 (en) | 2014-04-30 | 2017-10-31 | Incyte Corporation | Processes of preparing a JAK1 inhibitor and new forms thereto |
US9993480B2 (en) | 2011-02-18 | 2018-06-12 | Novartis Pharma Ag | mTOR/JAK inhibitor combination therapy |
US10064866B2 (en) | 2014-04-08 | 2018-09-04 | Incyte Corporation | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors |
US10166191B2 (en) | 2012-11-15 | 2019-01-01 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US10463667B2 (en) | 2007-06-13 | 2019-11-05 | Incyte Incorporation | Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US10758543B2 (en) | 2010-05-21 | 2020-09-01 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US10899736B2 (en) | 2018-01-30 | 2021-01-26 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US11103510B2 (en) | 2018-02-16 | 2021-08-31 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of cytokine-related disorders |
US11304949B2 (en) | 2018-03-30 | 2022-04-19 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
US11324749B2 (en) | 2018-10-31 | 2022-05-10 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
WO2022125670A1 (en) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
US11372003B2 (en) | 2018-04-13 | 2022-06-28 | Incyte Corporation | Biomarkers for graft-versus-host disease |
US11584961B2 (en) | 2018-03-30 | 2023-02-21 | Incyte Corporation | Biomarkers for inflammatory skin disease |
US11685731B2 (en) | 2020-06-02 | 2023-06-27 | Incyte Corporation | Processes of preparing a JAK1 inhibitor |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
US11999751B2 (en) | 2014-06-11 | 2024-06-04 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
PL3172209T3 (pl) * | 2014-07-25 | 2021-06-14 | Novartis Ag | Formulacja tabletkowa 2-fluoro-n-metylo-4-[7-(chinolin-6-ylometylo)imidazo[1,2-b][1,2,4]triazyn-2-ylo]benzamidu |
CZ2014773A3 (cs) * | 2014-11-10 | 2016-05-18 | Zentiva, K.S. | Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu |
CZ201629A3 (cs) * | 2016-01-22 | 2017-08-02 | Zentiva, K.S. | Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy |
WO2019096303A1 (zh) * | 2017-11-20 | 2019-05-23 | 江苏恒瑞医药股份有限公司 | 一种局部给药的药物组合物及其制备方法 |
WO2019104086A1 (en) | 2017-11-21 | 2019-05-31 | Denali Therapeutics Inc. | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
BR112020012611A2 (pt) | 2017-12-20 | 2020-12-08 | Denali Therapeutics Inc. | Processo para a preparação de compostos pirimidinil-4-aminopirazol |
AU2019208049A1 (en) * | 2018-01-09 | 2020-07-23 | Dermavant Sciences GmbH | Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof |
JP6830460B2 (ja) * | 2018-07-05 | 2021-02-17 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
MA54551A (fr) | 2018-12-20 | 2021-10-27 | Incyte Corp | Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine |
AU2020290995A1 (en) * | 2019-06-10 | 2022-04-07 | Incyte Corporation | Topical treatment of vitiligo by a JAK inhibitor |
MX2022002646A (es) | 2019-09-05 | 2022-04-26 | Incyte Corp | Formulacion de ruxolitinib para la reduccion de comezon en dermatitis atopica. |
WO2021102258A1 (en) | 2019-11-22 | 2021-05-27 | Incyte Corporation | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
US20230277537A1 (en) * | 2020-07-17 | 2023-09-07 | Pfizer Inc. | Stable pharmaceutical topical formulation containing immunosuppressant for treating dermatological condition |
PE20231743A1 (es) | 2020-08-18 | 2023-10-31 | Incyte Corp | Proceso e intermediarios para preparar un inhibidor de jak |
CA3192055A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
WO2022072814A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Topical ruxolitinib for treating lichen planus |
KR20230128472A (ko) | 2020-12-04 | 2023-09-05 | 인사이트 코포레이션 | 피부 질환의 치료를 위한 비타민 d 유사체를 함유하는jak 억제제 |
TW202308639A (zh) | 2021-05-03 | 2023-03-01 | 美商英塞特公司 | 用於治療結節性癢疹之鲁索替尼 |
CN113264936B (zh) * | 2021-05-25 | 2022-08-09 | 常州制药厂有限公司 | 一种jak抑制剂关键中间体及其制备方法 |
EP4370504A1 (en) | 2021-07-12 | 2024-05-22 | Incyte Corporation | Process and intermediates for preparing baricitinib |
CN115702936A (zh) * | 2021-08-13 | 2023-02-17 | 杭州中美华东制药有限公司 | 一种芦可替尼组合物及其用途 |
CN117750939A (zh) * | 2021-08-19 | 2024-03-22 | 珠海联邦制药股份有限公司 | 一种含有jak抑制剂或其盐或其晶型的局部外用制剂及其制备方法和应用 |
CN115869321A (zh) | 2021-09-28 | 2023-03-31 | 杭州中美华东制药有限公司 | 一种芦可替尼组合物及其制备方法 |
CN114870016B (zh) * | 2022-04-21 | 2023-05-26 | 上海博悦生物科技有限公司 | 一种jak抑制剂的微乳泡沫剂及其应用 |
US20230399331A1 (en) | 2022-06-14 | 2023-12-14 | Incyte Corporation | Solid forms of jak inhibitor and process of preparing the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075056A (en) * | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
WO2009158687A1 (en) * | 2008-06-26 | 2009-12-30 | Anterios, Inc. | Dermal delivery |
Family Cites Families (279)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2985589A (en) | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
US3832460A (en) | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
DE3220113A1 (de) | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | Difluormethoxiphenylthiophosphorsaeureester |
US4402832A (en) | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
US4498991A (en) | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
NL8403224A (nl) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
US5702688A (en) * | 1986-12-23 | 1997-12-30 | Tristrata Technology, Inc. | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
CA2067221C (en) | 1989-10-11 | 1997-04-15 | Yasuji Sakuma | Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient |
IT1258781B (it) | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
JPH0710876A (ja) | 1993-06-24 | 1995-01-13 | Teijin Ltd | 4位に環状アミノ基を有するピロロ[2,3―d]ピリミジン |
EP0727217A3 (en) | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient |
IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
BR9609613A (pt) | 1995-07-05 | 1999-05-25 | Du Pont | Composto composição fungicida e método de controle de doenças de plantas |
US5630943A (en) | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
CA2250232A1 (en) | 1996-04-03 | 1997-10-09 | Allen I. Oliff | A method of treating cancer |
AU2802297A (en) | 1996-04-18 | 1997-11-07 | Merck & Co., Inc. | A method of treating cancer |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
JP2000508335A (ja) | 1996-05-30 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | 癌の治療方法 |
US6624138B1 (en) | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
WO1998044797A1 (en) | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
US6063284A (en) | 1997-05-15 | 2000-05-16 | Em Industries, Inc. | Single column closed-loop recycling with periodic intra-profile injection |
US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
CA2295620A1 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,6-heteroaryl-dipyrido¬2,3-b:3',2'-f|azepines and their use in the prevention or treatment of hiv infection |
US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
CN1332743A (zh) | 1998-06-04 | 2002-01-23 | 艾博特公司 | 抑制细胞粘附抗炎化合物 |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
JP4516690B2 (ja) | 1998-08-11 | 2010-08-04 | ノバルティス アーゲー | 血管形成阻害活性を有するイソキノリン誘導体 |
JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
JP5026635B2 (ja) | 1998-09-10 | 2012-09-12 | ニュコメデ ダンマルク アンパーツセルスカブ | 医薬物質の迅速放出医薬組成物 |
US6375839B1 (en) | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
FR2785196B1 (fr) | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | Procede et dispositif de separation avec des zones chromatographiques a longueur variable |
US6413419B1 (en) | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
US6333384B1 (en) | 1998-11-02 | 2001-12-25 | Gil Technologies | Vinyl-terminated polybutadiene and butadiene-styrene copolymers containing urethane and/or ester residues, and the electrical laminates obtained therefrom |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
EP1165084A4 (en) | 1999-03-03 | 2002-05-15 | Merck & Co Inc | PRENYL PROTEIN TRANSFERASES INHIBITORS |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
AU3565999A (en) | 1999-04-16 | 2000-11-02 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
ATE275141T1 (de) | 1999-10-13 | 2004-09-15 | Banyu Pharma Co Ltd | Substituierte imidazolin-derivate |
DE60007552T2 (de) | 1999-12-10 | 2004-09-23 | Pfizer Products Inc., Groton | PYRROLO[2,3-d]PYRIMIDIN-VERBINDUNGEN ALS PROTEIN KINASEN HEMMER |
OA12514A (en) | 1999-12-24 | 2006-05-29 | Aventis Pharma Ltd | Azaindoles. |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
DE60100866T2 (de) | 2000-04-07 | 2004-07-29 | Laboratoire Medidom S.A. | Cyklosporin, Hyaluronsäure und Polysorbate enthaltenes Augenarzneimittel |
AU4878601A (en) | 2000-04-20 | 2001-11-07 | Mitsubishi Corporation | Aromatic amide compounds |
ES2527754T3 (es) | 2000-04-25 | 2015-01-29 | Icos Corporation | Inhibidores de la isoforma delta de la fosfatidilinositol 3-quinasa humana |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
US20030022819A1 (en) | 2000-06-16 | 2003-01-30 | Ling Leona E. | Angiogenesis-modulating compositions and uses |
US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
AU2001274598A1 (en) | 2000-06-23 | 2002-01-02 | Mitsubishi Pharma Corporation | Antitumor effect potentiators |
DE60137734D1 (de) | 2000-06-26 | 2009-04-02 | Pfizer Prod Inc | PyrroloÄ2,3-DÜpyrimidin Verbindungen als Immunosuppressive Wirkstoffe |
EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
AU2002228783A1 (en) | 2000-12-05 | 2002-06-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
US20040077654A1 (en) | 2001-01-15 | 2004-04-22 | Bouillot Anne Marie Jeanne | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
JP2004528295A (ja) | 2001-01-30 | 2004-09-16 | サイトピア ピーティワイ リミテッド | キナーゼ阻害方法 |
CA2446864C (en) | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of src and other protein kinases |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
WO2003011285A1 (en) | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES |
AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
US6429231B1 (en) | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
DK1441737T3 (da) | 2001-10-30 | 2006-11-13 | Novartis Ag | Staurosporin-derivater som inhibitorer af FLT3-receptor-tyrosinkinase-aktivitet |
JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
US6949668B2 (en) | 2001-11-30 | 2005-09-27 | Teijin Limited | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
ATE381332T1 (de) | 2002-05-02 | 2008-01-15 | Merck & Co Inc | Tyrosinkinase-hemmer |
EP1503731A1 (en) | 2002-05-07 | 2005-02-09 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
CN100558715C (zh) | 2002-05-23 | 2009-11-11 | 西托匹亚有限公司 | 蛋白激酶抑制剂 |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
US7385018B2 (en) | 2002-06-26 | 2008-06-10 | Idemitsu Kosan Co., Ltd. | Hydrogenated copolymer, process for producing the same, and hot-melt adhesive composition containing the same |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
EP1541563A4 (en) | 2002-07-10 | 2007-11-07 | Ono Pharmaceutical Co | ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE |
BR0314603A (pt) | 2002-09-20 | 2005-07-26 | Alcon Inc | Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos |
US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
ES2289349T3 (es) | 2002-11-04 | 2008-02-01 | Vertex Pharmaceuticals Incorporated | Derivados de heteroaril-pirimidina como inhibidores de jak. |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
US20040099204A1 (en) | 2002-11-25 | 2004-05-27 | Nestor John J. | Sheet, page, line, position marker |
AU2003276591A1 (en) | 2002-11-26 | 2004-06-18 | Pfizer Products Inc. | Method of treatment of transplant rejection |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
UY28126A1 (es) | 2002-12-24 | 2004-06-30 | Alcon Inc | Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular |
US7135493B2 (en) | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
US7444183B2 (en) | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
AU2004212421B2 (en) | 2003-02-07 | 2009-08-20 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US7547794B2 (en) | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
FR2857454B1 (fr) | 2003-07-08 | 2006-08-11 | Aventis Pasteur | Dosage des acides techoiques des bacteries gram+ |
US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
WO2005020921A2 (en) | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
DK1679074T3 (da) | 2003-10-24 | 2011-03-21 | Santen Pharmaceutical Co Ltd | Terapeutisk middel til keratoconjunktive forstyrrelser |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
BRPI0416909A (pt) | 2003-11-25 | 2007-01-16 | Pfizer Prod Inc | método de tratamento de aterosclerose |
CN1893952A (zh) | 2003-12-17 | 2007-01-10 | 辉瑞产品公司 | 用于治疗移植排斥的吡咯并[2,3-d]嘧啶化合物 |
CA2550189A1 (en) | 2003-12-19 | 2005-07-21 | Schering Corporation | Thiadiazoles as cxc- and cc- chemokine receptor ligands |
CA2550361C (en) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
CA2548374C (en) | 2003-12-23 | 2014-05-27 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
US20050187389A1 (en) | 2004-01-13 | 2005-08-25 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
WO2005089502A2 (en) | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
DK2332940T3 (da) | 2004-03-30 | 2013-02-11 | Vertex Pharma | Azaindoler, der kan anvendes som inhibitorer af JAK og andre proteinkinaser |
JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス, インコーポレイテッド | キナーゼ調節因子および使用方法 |
US7558717B2 (en) | 2004-04-28 | 2009-07-07 | Vertex Pharmaceuticals Incorporated | Crystal structure of human JAK3 kinase domain complex and binding pockets thereof |
US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
MXPA06012663A (es) | 2004-05-03 | 2007-01-16 | Novartis Ag | Combinaciones que comprenden un agonista del receptor s1p y un inhibidor de quinasa jak3. |
US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
MXPA06014247A (es) | 2004-06-10 | 2007-03-12 | Irm Llc | Compuestos y composiciones como inhibidores de la proteina quinasa. |
EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
CA2572058A1 (en) | 2004-06-30 | 2006-01-12 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
US7138423B2 (en) | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
FR2873691B1 (fr) | 2004-07-29 | 2006-10-06 | Sanofi Synthelabo | Derives d'amino-piperidine, leur preparation et leur application en therapeutique |
WO2006013114A1 (en) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
WO2006022459A1 (en) | 2004-08-23 | 2006-03-02 | Mogam Biotechnology Institute | Primer and probe for detection of sars coronavirus, kit comprising the primer and/or the probe, and detection method thereof |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
SI1802625T1 (sl) | 2004-10-13 | 2008-10-31 | Hoffmann La Roche | Disubstituirani pirazolobenzodiazepini, koristni kot inhibitorji za cdk2 in angiogenezo ter za zdravljenje prsnega raka, raka kolona, pljuäśnega rakain raka prostate |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
AU2005304784B2 (en) | 2004-11-04 | 2011-03-24 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
RU2007123675A (ru) | 2004-11-24 | 2008-12-27 | Новартис АГ (CH) | Комбинации ингибиторов jak |
US7517870B2 (en) | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
WO2006065916A1 (en) | 2004-12-14 | 2006-06-22 | Alcon, Inc. | Method of treating dry eye disorders using 13(s)-hode and its analogs |
WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
CA2595574A1 (en) | 2005-01-20 | 2006-07-27 | Pfizer Limited. | Chemical compounds |
ES2320487T3 (es) | 2005-02-03 | 2009-05-22 | Vertex Pharmaceuticals, Inc. | Pirrolopirimidinas utiles como inhibidores de proteina quinasas. |
WO2007044050A2 (en) | 2005-02-04 | 2007-04-19 | Bristol-Myers Squibb Company | 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
BRPI0608513A2 (pt) | 2005-03-15 | 2010-01-05 | Irm Llc | compostos e composições como inibidores da proteìna quinase |
MX2007012393A (es) | 2005-04-05 | 2008-02-22 | Pharmacopeia Inc | Derivados de purina e imidazopiridina para la inmunosupresion. |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
CA2609126A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CN105348203B (zh) | 2005-06-08 | 2018-09-18 | 里格尔药品股份有限公司 | 抑制jak途径的组合物和方法 |
WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
EP1893612B1 (en) | 2005-06-22 | 2011-08-03 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors |
CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
FR2889662B1 (fr) * | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
CA2621261C (en) | 2005-09-22 | 2014-05-20 | Incyte Corporation | Azepine inhibitors of janus kinases |
AU2006297351A1 (en) | 2005-09-30 | 2007-04-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
WO2007044894A2 (en) | 2005-10-11 | 2007-04-19 | Chembridge Research Laboratories, Inc. | Cell-free protein expression systems and methods of use thereof |
CA2623202C (en) | 2005-10-14 | 2014-09-16 | Sumitomo Chemical Company, Limited | Hydrazide compound and pesticidal use of the same |
BRPI0618011A2 (pt) | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente |
NZ567851A (en) | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007062459A1 (en) | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
SI2348023T1 (sl) | 2005-12-13 | 2015-10-30 | Incyte Corporation | S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze |
US20130137681A1 (en) | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
EP1968568A4 (en) | 2005-12-22 | 2011-04-13 | Glaxosmithkline Llc | HEMMER OF NUTS ACTIVITY |
PT1962830E (pt) | 2005-12-23 | 2013-05-29 | Glaxosmithkline Llc | Inibidores azaindólicos de cinases aurora |
TW201412738A (zh) | 2006-01-17 | 2014-04-01 | Vertex Pharma | 適合作為傑納斯激酶(janus kinase)抑制劑之氮雜吲哚 |
US20070208053A1 (en) | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
EP1981887A2 (en) | 2006-02-01 | 2008-10-22 | SmithKline Beecham Corporation | Pyrrolo[2,3,b]pyridine derivatives useful as raf kinase inhibitors |
US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
CA2644368A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
FR2898498B1 (fr) * | 2006-03-15 | 2008-11-28 | Galderma Sa | Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant |
BRPI0709866B8 (pt) | 2006-04-03 | 2021-05-25 | Astellas Pharma Inc | compostos héteros e composição farmacêutica compreendendo ditos compostos |
EP2001884A1 (en) | 2006-04-05 | 2008-12-17 | Vertex Pharmaceuticals, Inc. | Deazapurines useful as inhibitors of janus kinases |
US20090124636A1 (en) | 2006-04-12 | 2009-05-14 | Pfizer Inc. | Chemical compounds |
WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
US20080051427A1 (en) | 2006-05-18 | 2008-02-28 | Fritz Schuckler | Pharmaceutical Compositions and Methods of Using Same |
US7691811B2 (en) | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
EP2044061A2 (en) | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
US8715700B2 (en) * | 2006-07-21 | 2014-05-06 | Dow Pharmaceutical Sciences, Inc. | Alpha hydroxy acid sustained release formulation |
WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
CA2660560A1 (en) | 2006-08-16 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Pyrazine compounds, their use and methods of preparation |
JP2010502675A (ja) | 2006-09-08 | 2010-01-28 | ノバルティス アクチエンゲゼルシャフト | リンパ球相互作用が介在する疾患または障害を処置するために有用なn−ビアリール(ヘテロ)アリールスルホンアミド誘導体 |
WO2008035376A2 (en) | 2006-09-19 | 2008-03-27 | Council Of Scientific & Industrial Research | A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof |
CL2007002866A1 (es) | 2006-10-04 | 2008-07-04 | Pharmacopeia Inc | Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m |
CL2007002867A1 (es) | 2006-10-04 | 2008-06-27 | Pharmacopeia Inc | Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras. |
US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
WO2008058126A2 (en) | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
US20080119496A1 (en) | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
ME01507B (me) | 2006-11-22 | 2014-04-20 | Incyte Holdings Corp | Imidazotriazini i imidazopirimidini kao inhibitori kinaze |
WO2008067119A2 (en) | 2006-11-27 | 2008-06-05 | Smithkline Beecham Corporation | Novel compounds |
CA2672616A1 (en) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
ES2387471T3 (es) | 2006-12-20 | 2012-09-24 | Amgen Inc. | Compuestos heterocíclicos y su uso en el tratamiento de la inflamación, la angiogénesis y el cáncer |
WO2008079291A2 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
MX2009005644A (es) | 2006-12-22 | 2009-06-08 | Sigma Tau Ind Farmaceuti | Gel util para el suministro de farmacos oftalmicos. |
JP5492565B2 (ja) | 2006-12-22 | 2014-05-14 | インサイト・コーポレイション | Janusキナーゼ阻害剤としての置換複素環 |
KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
WO2008082840A1 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
US8822497B2 (en) | 2007-03-01 | 2014-09-02 | Novartis Ag | PIM kinase inhibitors and methods of their use |
ES2420113T3 (es) | 2007-04-03 | 2013-08-22 | Array Biopharma, Inc. | Compuestos de imidazo[1,2-a]piridina como inhibidores de receptores tirosina quinasa |
GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
WO2008145681A2 (en) | 2007-05-31 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
CU24179B1 (es) | 2007-06-13 | 2016-04-25 | Incyte Corp | SALES DE ÁCIDO MALEICO Y DE ÁCIDO SULFÚRICO DE (R)-3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CICLOPENTILPROPANITRILO |
CA2691914C (en) | 2007-07-11 | 2012-06-26 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
WO2009016460A2 (en) | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
EP2217235A4 (en) | 2007-11-15 | 2011-01-12 | Musc Found For Res Dev | PROTEIN INHIBITORS PIM KINASES, COMPOSITIONS AND METHODS FOR TREATING CANCER |
BRPI0820544A2 (pt) | 2007-11-16 | 2015-06-16 | Incyte Corp | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase |
GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
CN101977923B (zh) | 2008-01-18 | 2014-10-08 | 捷克有机化学和生物化学研究院 | 抑制细胞生长的7-脱氮嘌呤核苷 |
CA2714181C (en) | 2008-02-04 | 2013-12-24 | Mercury Therapeutics, Inc. | Ampk modulators |
AR070531A1 (es) | 2008-03-03 | 2010-04-14 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso |
BRPI0909040B8 (pt) | 2008-03-11 | 2021-05-25 | Incyte Holdings Corp | derivados de azetidina e ciclobutano, seus usos, e composição |
AU2009227013B2 (en) | 2008-03-21 | 2013-01-10 | Novartis Ag | Novel heterocyclic compounds and uses therof |
TWI461423B (zh) | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物 |
FR2933409B1 (fr) | 2008-07-03 | 2010-08-27 | Centre Nat Rech Scient | NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為pim激酶抑制劑之三唑吡啶化合物 |
WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
SI2384326T1 (sl) | 2008-08-20 | 2014-06-30 | Zoetis Llc | Pirolo(2,3-d)pirimidinske spojine |
US8329732B2 (en) | 2008-09-02 | 2012-12-11 | Novartis Ag | Kinase inhibitors and methods of their use |
BRPI0918846A2 (pt) | 2008-09-02 | 2019-09-24 | Novartis Ag | inibidores de cinase heterocíclica |
KR20110058866A (ko) | 2008-09-02 | 2011-06-01 | 노파르티스 아게 | 비시클릭 키나제 억제제 |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
EP2350054A4 (en) | 2008-10-17 | 2012-03-28 | Merck Canada Inc | AZETIDINE DERIVATIVES AS INHIBITORS OF THE STEAROYL COENZYME A DELTA 9 DESATURASE |
JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
HUE046493T2 (hu) | 2009-05-22 | 2020-03-30 | Incyte Holdings Corp | 3-[4-(7H-Pirrolo[2,3-d]pirimidin-4-il)-lH-pirazol-l-il]oktán- vagy heptán-nitril JAK inhibitorokként |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
CN101958119B (zh) | 2009-07-16 | 2012-02-29 | 中兴通讯股份有限公司 | 一种改进的离散余弦变换域音频丢帧补偿器和补偿方法 |
US20120157500A1 (en) | 2009-08-24 | 2012-06-21 | Weikang Tao | Jak inhibition blocks rna interference associated toxicities |
TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
SG10201405568UA (en) | 2009-09-08 | 2014-11-27 | Hoffmann La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
PT2486041E (pt) | 2009-10-09 | 2013-11-14 | Incyte Corp | Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo |
EP2491039A1 (en) | 2009-10-20 | 2012-08-29 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
EP2332917B1 (en) | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Compounds for PIM kinase inhibition and for treating malignancy |
WO2011066378A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat thrombosis |
US20130129675A1 (en) | 2009-12-04 | 2013-05-23 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
US8461328B2 (en) | 2010-01-12 | 2013-06-11 | Genentech, Inc. | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
JP5858434B2 (ja) | 2010-02-18 | 2016-02-10 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Janusキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体 |
DK3050882T3 (en) | 2010-03-10 | 2018-03-19 | Incyte Holdings Corp | PIPERIDIN-4-YL-AZETIDINE DERIVATIVES AS JAK1 INHIBITORS |
UA109131C2 (ru) | 2010-04-14 | 2015-07-27 | Еррей Біофарма Інк. | 5,7-ЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-c]ПИРИМИДИНЫ КАК ИНГИБИТОРЫ JAK-КИНАЗ |
EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
ME02445B (me) | 2010-05-21 | 2016-09-20 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
US8637529B2 (en) | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
US9351943B2 (en) | 2010-07-01 | 2016-05-31 | Matthew T. McLeay | Anti-fibroblastic fluorochemical emulsion therapies |
WO2012045010A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combinations of 4-(3-(2h-1,2,3-triazo-2-yl) phenylamino)-2-((1r,2s)-2-aminocyclohexylamino) pyrimidine-5-carboxamide and fludarabine |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
UA113156C2 (xx) | 2010-11-19 | 2016-12-26 | Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak | |
CN104473933A (zh) | 2010-12-03 | 2015-04-01 | Ym生物科学澳大利亚私人有限公司 | Jak-2 介导的病症的治疗 |
JP5936628B2 (ja) | 2011-02-18 | 2016-06-22 | ノバルティス・ファルマ・アクチェンゲゼルシャフトNovartis Pharma AG | mTOR/JAK阻害剤併用療法 |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
WO2013023119A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | JAK P13K/mTOR COMBINATION THERAPY |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
WO2014036016A1 (en) | 2012-08-31 | 2014-03-06 | Principia Biopharma Inc. | Benzimidazole derivatives as itk inhibitors |
SG10201703533VA (en) | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
PE20151157A1 (es) | 2012-11-15 | 2015-08-19 | Incyte Corp | Formas de dosificacion de ruxolitinib de liberacion sostenida |
PE20151902A1 (es) | 2013-03-06 | 2015-12-26 | Incyte Corp | Proceso e intermedios para hacer un inhibidor de jak |
EP4275756A3 (en) | 2013-05-17 | 2024-02-07 | Incyte Holdings Corporation | Bipyrazole derivatives as jak inhibitors |
RS60469B1 (sr) | 2013-08-07 | 2020-07-31 | Incyte Corp | Dozni oblici sa produženim oslobađanjem za jak1 inhibitor |
MX2016002165A (es) | 2013-08-20 | 2017-01-05 | Incyte Corp | Beneficio de supervivencia en pacientes con tumores solidos con niveles elevados de proteina c reactiva. |
SI3110409T1 (sl) | 2014-02-28 | 2018-11-30 | Incyte Corporation | Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov |
MA54622A (fr) | 2014-04-08 | 2021-11-03 | Incyte Corp | Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné |
SG11201609016VA (en) | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
ES2946179T3 (es) | 2014-05-28 | 2023-07-13 | Onco Tracker Inc | Efectos antineoplásicos de inhibidores de JAK2 en combinación con derivados de talidomida y glucocorticoides |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
-
2011
- 2011-05-20 ME MEP-2016-92A patent/ME02445B/me unknown
- 2011-05-20 EA EA202091303A patent/EA202091303A3/ru unknown
- 2011-05-20 UA UAA201214654A patent/UA111588C2/uk unknown
- 2011-05-20 SG SG10201910912TA patent/SG10201910912TA/en unknown
- 2011-05-20 PL PL11724104.2T patent/PL2574168T3/pl unknown
- 2011-05-20 US US13/112,370 patent/US20110288107A1/en not_active Abandoned
- 2011-05-20 CA CA2799928A patent/CA2799928C/en active Active
- 2011-05-20 EA EA201291310A patent/EA035981B1/ru unknown
- 2011-05-20 DK DK11724104.2T patent/DK2574168T3/en active
- 2011-05-20 SI SI201130813A patent/SI2574168T1/sl unknown
- 2011-05-20 JP JP2013511374A patent/JP5849312B2/ja active Active
- 2011-05-20 RS RS20160298A patent/RS54824B1/sr unknown
- 2011-05-20 KR KR1020217029425A patent/KR102402137B1/ko active IP Right Grant
- 2011-05-20 KR KR1020187025131A patent/KR102040479B1/ko active IP Right Grant
- 2011-05-20 KR KR1020227017111A patent/KR102635013B1/ko active IP Right Grant
- 2011-05-20 HU HUE11724104A patent/HUE029035T2/en unknown
- 2011-05-20 KR KR1020127033308A patent/KR101921466B1/ko active IP Right Grant
- 2011-05-20 AU AU2011255443A patent/AU2011255443B2/en active Active
- 2011-05-20 BR BR112012029653-1A patent/BR112012029653B1/pt active IP Right Grant
- 2011-05-20 MX MX2012013400A patent/MX338228B/es active IP Right Grant
- 2011-05-20 MY MYPI2012004949A patent/MY161078A/en unknown
- 2011-05-20 SG SG10201503983QA patent/SG10201503983QA/en unknown
- 2011-05-20 KR KR1020197032033A patent/KR102303885B1/ko active IP Right Grant
- 2011-05-20 AR ARP110101747A patent/AR084691A1/es not_active Application Discontinuation
- 2011-05-20 NZ NZ603686A patent/NZ603686A/en unknown
- 2011-05-20 ES ES11724104.2T patent/ES2581834T3/es active Active
- 2011-05-20 EP EP16160077.0A patent/EP3087972A1/en not_active Withdrawn
- 2011-05-20 WO PCT/US2011/037291 patent/WO2011146808A2/en active Application Filing
- 2011-05-20 PE PE2012002197A patent/PE20130216A1/es active IP Right Grant
- 2011-05-20 CN CN201610207261.XA patent/CN105853356B/zh active Active
- 2011-05-20 MY MYPI2016000077A patent/MY178634A/en unknown
- 2011-05-20 TW TW100117866A patent/TWI499421B/zh active
- 2011-05-20 CN CN201180035301.2A patent/CN103002875B/zh active Active
- 2011-05-20 EP EP11724104.2A patent/EP2574168B9/en active Active
- 2011-05-20 SG SG2012083739A patent/SG185567A1/en unknown
-
2012
- 2012-11-15 IL IL223084A patent/IL223084A/en active IP Right Grant
- 2012-11-20 CL CL2012003229A patent/CL2012003229A1/es unknown
- 2012-11-23 CO CO12213010A patent/CO6640250A2/es unknown
- 2012-11-30 CR CR20120605A patent/CR20120605A/es unknown
-
2013
- 2013-04-11 EC ECSP13012546 patent/ECSP13012546A/es unknown
- 2013-08-16 HK HK13109607.1A patent/HK1182313A1/zh unknown
-
2014
- 2014-05-28 AU AU2014202896A patent/AU2014202896A1/en not_active Abandoned
-
2015
- 2015-05-18 US US14/714,820 patent/US20150250790A1/en not_active Abandoned
- 2015-11-09 JP JP2015219637A patent/JP2016053069A/ja active Pending
-
2016
- 2016-06-16 SM SM201600172T patent/SMT201600172B/it unknown
- 2016-07-06 AU AU2016204689A patent/AU2016204689A1/en not_active Abandoned
- 2016-07-12 HR HRP20160841TT patent/HRP20160841T1/hr unknown
- 2016-07-19 CY CY20161100706T patent/CY1117815T1/el unknown
-
2017
- 2017-04-04 JP JP2017074531A patent/JP6479877B2/ja active Active
-
2018
- 2018-03-16 AU AU2018201889A patent/AU2018201889B2/en active Active
-
2019
- 2019-02-06 JP JP2019019674A patent/JP6657441B2/ja active Active
- 2019-09-10 US US16/566,625 patent/US10758543B2/en active Active
-
2020
- 2020-02-05 JP JP2020018063A patent/JP6952143B2/ja active Active
- 2020-02-18 AU AU2020201151A patent/AU2020201151B2/en active Active
- 2020-05-04 ZA ZA2020/01999A patent/ZA202001999B/en unknown
- 2020-08-14 US US16/947,735 patent/US10869870B2/en active Active
- 2020-09-17 US US16/948,408 patent/US11219624B2/en active Active
-
2021
- 2021-09-27 JP JP2021157016A patent/JP7167280B2/ja active Active
- 2021-11-24 AR ARP210103240A patent/AR124134A2/es unknown
- 2021-12-03 US US17/541,439 patent/US20220211707A1/en active Pending
-
2022
- 2022-03-25 US US17/704,168 patent/US11571425B2/en active Active
- 2022-03-25 US US17/704,155 patent/US20220370455A1/en not_active Abandoned
- 2022-03-25 US US17/704,180 patent/US11590136B2/en active Active
- 2022-07-05 AU AU2022204807A patent/AU2022204807B2/en active Active
- 2022-10-26 JP JP2022171523A patent/JP7547435B2/ja active Active
- 2022-12-28 US US18/089,651 patent/US20230277541A1/en active Pending
-
2024
- 2024-02-27 US US18/588,626 patent/US20240245687A1/en active Pending
- 2024-05-07 EC ECSENADI202434690A patent/ECSP24034690A/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075056A (en) * | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
WO2009158687A1 (en) * | 2008-06-26 | 2009-12-30 | Anterios, Inc. | Dermal delivery |
Cited By (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9974790B2 (en) | 2005-12-13 | 2018-05-22 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
US11331320B2 (en) | 2005-12-13 | 2022-05-17 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US8933086B2 (en) | 2005-12-13 | 2015-01-13 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors |
US9662335B2 (en) | 2005-12-13 | 2017-05-30 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
US11744832B2 (en) | 2005-12-13 | 2023-09-05 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US9814722B2 (en) | 2005-12-13 | 2017-11-14 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
US8530485B2 (en) | 2005-12-13 | 2013-09-10 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US8415362B2 (en) | 2005-12-13 | 2013-04-09 | Incyte Corporation | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US9206187B2 (en) | 2005-12-13 | 2015-12-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase |
US9079912B2 (en) | 2005-12-13 | 2015-07-14 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
US10398699B2 (en) | 2005-12-13 | 2019-09-03 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
US8541425B2 (en) | 2005-12-13 | 2013-09-24 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US10639310B2 (en) | 2005-12-13 | 2020-05-05 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US8946245B2 (en) | 2005-12-13 | 2015-02-03 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US8722693B2 (en) | 2007-06-13 | 2014-05-13 | Incyte Corporation | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US9376439B2 (en) | 2007-06-13 | 2016-06-28 | Incyte Corporation | Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US10016429B2 (en) | 2007-06-13 | 2018-07-10 | Incyte Corporation | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US8822481B1 (en) | 2007-06-13 | 2014-09-02 | Incyte Corporation | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US10610530B2 (en) | 2007-06-13 | 2020-04-07 | Incyte Corporation | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US8829013B1 (en) | 2007-06-13 | 2014-09-09 | Incyte Corporation | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US10463667B2 (en) | 2007-06-13 | 2019-11-05 | Incyte Incorporation | Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US11213528B2 (en) | 2007-06-13 | 2022-01-04 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US9000161B2 (en) | 2009-01-15 | 2015-04-07 | Incyte Corporation | Processes for preparing JAK inhibitors and related intermediate compounds |
US10364248B2 (en) | 2009-01-15 | 2019-07-30 | Incyte Corporation | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine |
US9290506B2 (en) | 2009-01-15 | 2016-03-22 | Incyte Corporation | Processes for preparing JAK inhibitors and related intermediate compounds |
US8993582B2 (en) | 2009-01-15 | 2015-03-31 | Incyte Corporation | Processes for preparing JAK inhibitors and related intermediate compounds |
US10975085B2 (en) | 2009-01-15 | 2021-04-13 | Incyte Holdings Corporation | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III |
US8883806B2 (en) | 2009-01-15 | 2014-11-11 | Incyte Corporation | Processes for preparing JAK inhibitors and related intermediate compounds |
US9908888B2 (en) | 2009-01-15 | 2018-03-06 | Incyte Corporation | Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines |
US9216984B2 (en) | 2009-05-22 | 2015-12-22 | Incyte Corporation | 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors |
US9334274B2 (en) | 2009-05-22 | 2016-05-10 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9623029B2 (en) | 2009-05-22 | 2017-04-18 | Incyte Holdings Corporation | 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US8604043B2 (en) | 2009-05-22 | 2013-12-10 | Incyte Corporation | 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9999619B2 (en) | 2010-03-10 | 2018-06-19 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US11285140B2 (en) | 2010-03-10 | 2022-03-29 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US8765734B2 (en) | 2010-03-10 | 2014-07-01 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US10695337B2 (en) | 2010-03-10 | 2020-06-30 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US9464088B2 (en) | 2010-03-10 | 2016-10-11 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US10758543B2 (en) | 2010-05-21 | 2020-09-01 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US10869870B2 (en) | 2010-05-21 | 2020-12-22 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US11219624B2 (en) | 2010-05-21 | 2022-01-11 | Incyte Holdings Corporation | Topical formulation for a JAK inhibitor |
US11590136B2 (en) | 2010-05-21 | 2023-02-28 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US11571425B2 (en) | 2010-05-21 | 2023-02-07 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
US8933085B2 (en) | 2010-11-19 | 2015-01-13 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US10640506B2 (en) | 2010-11-19 | 2020-05-05 | Incyte Holdings Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors |
US9993480B2 (en) | 2011-02-18 | 2018-06-12 | Novartis Pharma Ag | mTOR/JAK inhibitor combination therapy |
US9611269B2 (en) | 2011-06-20 | 2017-04-04 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US9023840B2 (en) | 2011-06-20 | 2015-05-05 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US11214573B2 (en) | 2011-06-20 | 2022-01-04 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US10513522B2 (en) | 2011-06-20 | 2019-12-24 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
US9359358B2 (en) | 2011-08-18 | 2016-06-07 | Incyte Holdings Corporation | Cyclohexyl azetidine derivatives as JAK inhibitors |
US9487521B2 (en) | 2011-09-07 | 2016-11-08 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US9718834B2 (en) | 2011-09-07 | 2017-08-01 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US11161855B2 (en) | 2012-11-01 | 2021-11-02 | Incyte Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
US9181271B2 (en) | 2012-11-01 | 2015-11-10 | Incyte Holdings Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
US10370387B2 (en) | 2012-11-01 | 2019-08-06 | Incyte Holdings Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
US9908895B2 (en) | 2012-11-01 | 2018-03-06 | Incyte Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
US9777017B2 (en) | 2012-11-01 | 2017-10-03 | Incyte Holdings Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
US11851442B2 (en) | 2012-11-01 | 2023-12-26 | Incyte Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
US11337927B2 (en) | 2012-11-15 | 2022-05-24 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
US10166191B2 (en) | 2012-11-15 | 2019-01-01 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US11576864B2 (en) | 2012-11-15 | 2023-02-14 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US11576865B2 (en) | 2012-11-15 | 2023-02-14 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US10874616B2 (en) | 2012-11-15 | 2020-12-29 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US11896717B2 (en) | 2012-11-15 | 2024-02-13 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
US9714233B2 (en) | 2013-03-06 | 2017-07-25 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US8987443B2 (en) | 2013-03-06 | 2015-03-24 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US9221845B2 (en) | 2013-03-06 | 2015-12-29 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US11001571B2 (en) | 2013-05-17 | 2021-05-11 | Incyte Corporation | Bipyrazole derivatives as JAK inhibitors |
US9926301B2 (en) | 2013-05-17 | 2018-03-27 | Incyte Corporation | Bipyrazole derivatives as JAK inhibitors |
US9382231B2 (en) | 2013-05-17 | 2016-07-05 | Incyte Corporation | Bipyrazole derivatives as JAK inhibitors |
US10435392B2 (en) | 2013-05-17 | 2019-10-08 | Incyte Corporation | Bipyrazole derivatives as JAK inhibitors |
US11905275B2 (en) | 2013-05-17 | 2024-02-20 | Incyte Corporation | Bipyrazole derivatives as JAK inhibitors |
US11591318B2 (en) | 2013-05-17 | 2023-02-28 | Incyte Corporation | Bipyrazole derivatives as JAK inhibitors |
US9655854B2 (en) | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US10561616B2 (en) | 2013-08-07 | 2020-02-18 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US11045421B2 (en) | 2013-08-07 | 2021-06-29 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US10064866B2 (en) | 2014-04-08 | 2018-09-04 | Incyte Corporation | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors |
US10675284B2 (en) | 2014-04-08 | 2020-06-09 | Incyte Corporation | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors |
US10450325B2 (en) | 2014-04-30 | 2019-10-22 | Incyte Corporation | Processes of preparing a JAK1 inhibitor and new forms thereto |
US9802957B2 (en) | 2014-04-30 | 2017-10-31 | Incyte Corporation | Processes of preparing a JAK1 inhibitor and new forms thereto |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US11999751B2 (en) | 2014-06-11 | 2024-06-04 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
US11278541B2 (en) | 2017-12-08 | 2022-03-22 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US10899736B2 (en) | 2018-01-30 | 2021-01-26 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US11833152B2 (en) | 2018-02-16 | 2023-12-05 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of cytokine-related disorders |
US11103510B2 (en) | 2018-02-16 | 2021-08-31 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of cytokine-related disorders |
US11304949B2 (en) | 2018-03-30 | 2022-04-19 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
US11584961B2 (en) | 2018-03-30 | 2023-02-21 | Incyte Corporation | Biomarkers for inflammatory skin disease |
US11372003B2 (en) | 2018-04-13 | 2022-06-28 | Incyte Corporation | Biomarkers for graft-versus-host disease |
US12099068B2 (en) | 2018-04-13 | 2024-09-24 | Incyte Corporation | Biomarkers for graft-versus-host disease |
US11324749B2 (en) | 2018-10-31 | 2022-05-10 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
US11685731B2 (en) | 2020-06-02 | 2023-06-27 | Incyte Corporation | Processes of preparing a JAK1 inhibitor |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
US11957661B2 (en) | 2020-12-08 | 2024-04-16 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of vitiligo |
WO2022125670A1 (en) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11571425B2 (en) | Topical formulation for a JAK inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INCYTE CORPORATION, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARIKH, BHAVNISH;SHAH, BHAVESH;YELESWARAM, KRISHNASWAMY;SIGNING DATES FROM 20110715 TO 20110720;REEL/FRAME:026641/0350 |
|
AS | Assignment |
Owner name: INCYTE HOLDINGS CORPORATION AND INCYTE CORPORATION Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INCYTE CORPORATION;REEL/FRAME:035924/0004 Effective date: 20150107 |
|
AS | Assignment |
Owner name: INCYTE HOLDINGS CORPORATION, DELAWARE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE OMMISSION OF SECOND RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 035292 FRAME: 0004. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:INCYTE CORPORATION;REEL/FRAME:036054/0696 Effective date: 20150107 Owner name: INCYTE CORPORATION, DELAWARE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE OMMISSION OF SECOND RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 035292 FRAME: 0004. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:INCYTE CORPORATION;REEL/FRAME:036054/0696 Effective date: 20150107 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |